To evaluate the prognostic risk related to the enhancer-controlled genes associated with ATR pathway activation, we calculated the hazard ratio and 95% confidence interval (CI) of the overall survival of glioma patients using Cox proportional hazard models. This evidence concerns the gene ATR and central nervous system cancer.